In 589 adults hospitalised with COVID-19, ensitrelvir added to standard care did not improve clinical recovery to day 60 versus placebo (OR 0.82, P=.19). Mortality was 6.1% vs 4.4% and haemorrhagic events 3.4% vs 0.3% with ensitrelvir.
RCTn = 589
Baker et al. Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial